Retatrutide: Double the Weight Loss, Better Blood Sugar

Eli Lilly's investigational drug, retatrutide, has demonstrated significant advantages over Ozempic in a Phase 3 clinical trial. The trial, involving over 1,000 adults with type 2 diabetes, revealed that retatrutide yielded substantially greater weight loss and improved blood sugar management compared to Ozempic. Participants on higher doses of retatrutide lost an average of nearly 47 pounds, more than double the weight loss achieved with Ozempic, and saw a greater reduction in their A1C levels.

Retatrutide, a once-weekly injection, functions by mimicking three hormones: GLP-1, GIP, and glucagon. This mechanism, earning it the 'triple-G' moniker, distinguishes it from existing drugs that target fewer hormones. Beyond weight and blood sugar, retatrutide also showed positive impacts on cholesterol and blood pressure. Eli Lilly anticipates submitting retatrutide for U.S. Food and Drug Administration approval in early 2027, potentially transforming treatment for diabetes and obesity.